Clinical Trials Directory

Trials / Completed

CompletedNCT02886468

DEpth of EPinephrine Delivery With Auto-injectors Devices

Determinants of Muscle - Skin Distance at the Injection Site in Patients With an Indication for the Use of Epinephrine Auto- Injector Pens

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
107 (actual)
Sponsor
Centre Hospitalier Régional Metz-Thionville · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. Although there are several causes of fatal anaphylaxis, food allergy is one of the most common. Epinephrine is recommended as the initial treatment of choice for anaphylaxis. A delay in epinephrine administration may contribute to an increased risk of death. Therefore, the World Allergy Organization recommends that, for the treatment of anaphylaxis, epinephrine solution be administered intramuscularly in the mid-anterolateral thigh. In France 3 auto-injector pens are available: Anapen®, Epipen® and Jext®. For weight\> 30 kg, the devices have a needle size respectively of 7.49 mm, 15.02 mm and 15.36 mm. For the weights between 15 and 30 kg needle size is 7.49 mm to 12.7 mm and Anapen® for Epipen® and Jext®. Several studies suggest that the needle length needle is sometim

Conditions

Interventions

TypeNameDescription
OTHERskin ultrasound

Timeline

Start date
2016-08-26
Primary completion
2021-05-04
Completion
2021-08-16
First posted
2016-09-01
Last updated
2021-08-26

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02886468. Inclusion in this directory is not an endorsement.